- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04075435
Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia (CBD)
March 7, 2024 updated by: Staci Gruber, Ph.D., Mclean Hospital
Open-Label Trial of a Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia
This is an open label, eight week, clinical trial of a proprietary high CBD/low THC sublingual solution for the treatment of clinically significant anxiety and agitation in individuals with mild cognitive impairment (MCI) or mild to moderate Alzheimer's Disease (AD).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
12
Phase
- Early Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Rosain C Ozonsi, BS
- Phone Number: 617-855-2511
- Email: rozonsi@mclean.harvard.edu
Study Contact Backup
- Name: Rosemary Smith, MS
- Phone Number: 617-855-2908
- Email: rsmith@mclean.harvard.edu
Study Locations
-
-
Massachusetts
-
Belmont, Massachusetts, United States, 02478
- Recruiting
- McLean Hospital
-
Principal Investigator:
- Staci Gruber, PhD
-
Contact:
- Ipsit V Vahia, MD
- Phone Number: 617-855-3291
- Email: ivahia@mclean.harvard.edu
-
Principal Investigator:
- Ipsit Vahia, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years to 90 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of probable Alzheimer's Dementia via criteria from McKhann et al., or MCI
- MMSE score of 15-30 (inclusive)
- Clinically significant degree of anxiety, as defined by a Clinical Impression total column score of ≥4 on the Anxiety domain of the NPI-C
- A health care proxy available to sign consent on behalf of the participant (if applicable)
- A caregiver who spends at least 10 hours per week with the subject who is able to attend all study visits
- Participants and their study partner must be fluent in English
- Must be 60-90 years old (inclusive)
Exclusion Criteria:
- Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic or hematologic disease, which might confound assessment of safety outcomes.
- Seizure disorder
- Lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, as determined by the MINI
- Current episode of major depression, as determined by the MINI
- Active substance abuse or dependence within the past 6 months, as determined by the MINI
- Delirium (as measured by the CAM)
- Current inpatient hospitalization
- Current regular use of cannabinoid products (>1 use per month)
- Positive urine screen for THC at the screening or baseline visit
- Allergy to coconut
- Participants taking strong inhibitors or inducers of CYP3A4 (e.g. fluconazole, fluoxetine, fluvoxamine, ticlopidine, St. John's Wort, etc.), CYP2C19 (ketoconazole, erythromycin, etc.), or anti-epileptic drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: All subjects
This arm will include all subjects, individuals will administer a high CBD, low THC full spectrum sublingual solution twice daily on a variable dosing schedule.
|
Hemp derived solution to be administered sublingually twice daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total of clinician impression column on anxiety domain of the NPI-C
Time Frame: Continuous, weeks 0-8
|
Measure of Anxiety Domain on the Neuropsychiatric Inventory-Clinician scale
|
Continuous, weeks 0-8
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total score on the Generalized Anxiety Disorder 7 scale
Time Frame: Continuous, week 0-8
|
Secondary Outcome Measure of anxiety reduction
|
Continuous, week 0-8
|
Number of serious adverse events
Time Frame: Continuous, weeks 0-8
|
Secondary Outcome Measure of safety defined by absence of serious adverse events
|
Continuous, weeks 0-8
|
Week 8 MMSE total score compared to baseline MMSE total score
Time Frame: longitudinal: screening/baseline and week8
|
Secondary Outcome Measure of safety as defined by lack of treatment emergent cognitive impairment as measured by the Mini Mental Status Exam (MMSE)
|
longitudinal: screening/baseline and week8
|
Score on the confusion assessment method
Time Frame: Continuous screening weeks 0-8, dichotomous
|
Secondary Outcome Measure of safety defined as absence of treatment emergent delirium as measured by the Confusion Assessment Method (CAM)
|
Continuous screening weeks 0-8, dichotomous
|
Number and severity of side effects reported
Time Frame: Continuous, weeks 0-8
|
Secondary Outcome Measure of safety defined as a low number of emergent somatic side effects as measured by the Medication Side Effects Questionnaire
|
Continuous, weeks 0-8
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total clinical impression column score on neuropsychiatric inventory agitation and aggression domains (NPI-C)
Time Frame: Continuous, weeks 0-8
|
Exploratory measure to see reduction in agitation and aggression symptoms
|
Continuous, weeks 0-8
|
Total score of Cohen-Mansfield Inventory (CMAI)
Time Frame: Continuous, weeks 0-8
|
Exploratory measure to see reduction in agitation symptoms
|
Continuous, weeks 0-8
|
Total Score of Zarit Caregiver Burden Interview
Time Frame: Continuous, weeks 0-8
|
Exploratory downstream reduction in caregiver burden
|
Continuous, weeks 0-8
|
Stability of anxiety and agitation reduction using anxiety domain of NPI-C and GAD-7
Time Frame: Months 3, 6, 9, and 12 of the optional follow-up phase
|
Exploratory investigation into the stability of anxiety reduction using the anxiety domain score on the NPI-C and the GAD-7 during the optional follow-up phase
|
Months 3, 6, 9, and 12 of the optional follow-up phase
|
Stability of caregiver burden reduction
Time Frame: Months 3, 6, 9, and 12 of the optional follow-up phase
|
Exploratory investigation into reduction of caregiver burden using the Zarit Caregiver Burden Interview during the optional follow-up phase
|
Months 3, 6, 9, and 12 of the optional follow-up phase
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Staci Gruber, PhD, McLean Hospital
- Principal Investigator: Ipsit V Vahia, MD, McLean Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2021
Primary Completion (Estimated)
September 15, 2024
Study Completion (Estimated)
September 15, 2024
Study Registration Dates
First Submitted
August 29, 2019
First Submitted That Met QC Criteria
August 29, 2019
First Posted (Actual)
August 30, 2019
Study Record Updates
Last Update Posted (Actual)
March 8, 2024
Last Update Submitted That Met QC Criteria
March 7, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Dyskinesias
- Psychomotor Disorders
- Tauopathies
- Cognition Disorders
- Aberrant Motor Behavior in Dementia
- Psychomotor Agitation
- Dementia
- Alzheimer Disease
- Cognitive Dysfunction
- Behavioral Symptoms
Other Study ID Numbers
- 2019P002466
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anxiety
-
AstraZenecaCompletedAnxiety Disorders | Anxiety | Anxiety Neuroses | Anxiety StatesUnited States
-
Prisma Health-UpstateCompletedAnxiety | Anxiety, Separation | Separation Anxiety | Anxiety Generalized
-
Ann & Robert H Lurie Children's Hospital of ChicagoUniversity of California, Los Angeles; University of CincinnatiRecruitingAnxiety, Separation | Anxiety, Social | Anxiety, GeneralizedUnited States
-
Yale UniversityNational Institute of Mental Health (NIMH)Active, not recruitingGeneralized Anxiety Disorder | Anxiety Disorder of Childhood | Separation Anxiety Disorder of Childhood | Social Anxiety Disorder of ChildhoodUnited States
-
Nazife Begüm KARANCompletedDental Anxiety | Sedative; Anxiety DisorderTurkey
-
Loyola UniversityCompletedAnxiety | Anxiety State | Procedural AnxietyUnited States
-
Eli Lilly and CompanyCompletedAnxiety Neuroses | Anxiety States, Neurotic | Neuroses, AnxietyUnited States, Mexico, South Africa
-
West University of TimisoaraUnknownAnxiety Disorder/Anxiety StateRomania
-
Dr. Nazanin AlaviActive, not recruitingGeneralized Anxiety Disorder | AnxietyCanada
-
ProofPilotFisher WallaceActive, not recruitingGeneralized Anxiety Disorder | Anxiety | Generalized AnxietyUnited States
Clinical Trials on high CBD/low THC sublingual solution
-
Jamie BurrActive, not recruitingCannabis | Cardiovascular Risk FactorCanada
-
TilrayUniversity of British ColumbiaCompletedPosttraumatic Stress DisorderCanada
-
New York State Psychiatric InstituteWithdrawn
-
St. Joseph's Healthcare HamiltonMcMaster UniversityRecruitingDepression | Sleep Disorder | Insomnia | Depressive Disorder, Major | Insomnia ChronicCanada
-
Hartford HospitalYale UniversityNot yet recruitingMarijuana Use | Cannabis Use | Cannabis Intoxication
-
New York State Psychiatric InstituteWithdrawn
-
University of California, Los AngelesNational Center for Complementary and Integrative Health (NCCIH)Recruiting
-
Multidisciplinary Association for Psychedelic StudiesCompletedPosttraumatic Stress DisorderUnited States
-
University of British ColumbiaRecruiting
-
Meiji Seika Pharma Co., Ltd.Completed